+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
ID06466382

OV Precision Trial Evaluating Personalized Molecular Tumor Board Therapy Versus Standard Chemotherapy for Advanced Ovarian Cancer

Led by Swiss GO Trial Group · Updated on 2026-10-27

60

Participants Needed

10

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding detailed tumor and patient-specific biological information improves treatment decisions and outcomes for ovarian cancer patients with homologous recombination proficient HRP or HRD negative tumors. These patients usually have a poor prognosis similar to platinum-resistant cases, and current standard chemotherapy options are limited. The study focuses on personalized treatment recommendations using advanced tumor profiling to guide therapy choices beyond standard care. The study compares two groups one receiving standard chemotherapy with carboplatin and paclitaxel, either every three weeks or weekly, and another receiving treatment recommendations from a molecular tumor board based on a detailed molecular summary report derived from tumor profiling. This report combines multiple precision-cancer profiling methods to identify the most promising drugs or experimental therapies tailored to each patients tumor biology. The trial includes an initial diagnostic phase for HRD testing and tumor profiling, followed by randomization of HRD-negative patients to one of the two treatment approaches. Participants will be closely monitored throughout the study, which lasts about three years including analysis time. Researchers assess how often the tumor board recommends different treatments, how supported oncologists feel by these recommendations, differences in treatment decisions between patients and doctors, and preliminary patient benefits. Patients will undergo regular visits and evaluations to track treatment decisions and outcomes under medical supervision, ensuring safety and adherence to protocols.

CONDITIONS

Brief Title

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Research Team

M

Maren S Vogel, PhD

T

Team Swiss GO Trial Group

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here